Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

NCT02515630 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis (PMF)
Post-polycythemia Vera (Post-PV) Myelofibrosis
Postessential Thrombocythemia (Post-ET) Myelofibrosis

Interventions

DRUG: MMB

Sponsor

Sierra Oncology LLC - a GSK company